Scholarlink

Background <p>Breast cancer is one of the major global health concerns, and the investigation of mutations in the <i>BRCA1</i> gene is essential for prevention and treatment. Carriers of pathogenic <i>BRCA1</i> gene variants face an increased risk of breast cancer during their lifespan. Mutations in exons 2 and 16 of the <i>BRCA1</i> gene are common; thus, the study was designed to determine mutations in these exons.</p> Methods <p>In the present study, 40 breast cancer patients, including 20 with a positive family history, were examined for <i>BRCA1</i> mutation. The <i>BRCA1</i> gene was analyzed through direct PCR product sequencing. Polyphen-2, sorting intolerant from tolerant (SIFT), and Protein variation effect analyzer (PROVEAN) software were used to predict the role of variants on protein function.</p> Results <p>Six of the breast cancer patients (15%) carried the heterozygous missense polymorphism c.4837A &gt; G (p. Ser1613Gly) in exon 16. In exon 16 of the <i>BRCA1</i> gene, three homozygous variants (7.5%) c.4837A &gt; G (p. Ser1613Gly) were observed. c.4803delA mutation was detected in 4 patients (10%) in exon 16 of the <i>BRCA1</i> gene, a novel and pathogenic mutation.</p> Conclusion <p>Women carrying mutations in the <i>BRCA1</i> gene face a significantly increased lifetime risk of breast cancer-related mortality. Therefore, it is vital to detect <i>BRCA1</i> gene mutation in carrier women before the onset of cancer so that subsequent preventive strategies such as surgical prevention and chemoprevention can be implemented.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prevalence of BRCA1 gene mutations in female breast cancer patients in Mazandaran Province, Northern Iran

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月17日

查看全文
  • Masoumeh Jangjou,
  • Majid Alipour,
  • Ramin Mofarrah,
  • Soroush Alipour

摘要

Background

Breast cancer is one of the major global health concerns, and the investigation of mutations in the BRCA1 gene is essential for prevention and treatment. Carriers of pathogenic BRCA1 gene variants face an increased risk of breast cancer during their lifespan. Mutations in exons 2 and 16 of the BRCA1 gene are common; thus, the study was designed to determine mutations in these exons.

Methods

In the present study, 40 breast cancer patients, including 20 with a positive family history, were examined for BRCA1 mutation. The BRCA1 gene was analyzed through direct PCR product sequencing. Polyphen-2, sorting intolerant from tolerant (SIFT), and Protein variation effect analyzer (PROVEAN) software were used to predict the role of variants on protein function.

Results

Six of the breast cancer patients (15%) carried the heterozygous missense polymorphism c.4837A > G (p. Ser1613Gly) in exon 16. In exon 16 of the BRCA1 gene, three homozygous variants (7.5%) c.4837A > G (p. Ser1613Gly) were observed. c.4803delA mutation was detected in 4 patients (10%) in exon 16 of the BRCA1 gene, a novel and pathogenic mutation.

Conclusion

Women carrying mutations in the BRCA1 gene face a significantly increased lifetime risk of breast cancer-related mortality. Therefore, it is vital to detect BRCA1 gene mutation in carrier women before the onset of cancer so that subsequent preventive strategies such as surgical prevention and chemoprevention can be implemented.